533 related articles for article (PubMed ID: 30020140)
1. Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?
Kalra PA; Burlacu A; Ferro CJ; Covic A
Curr Opin Nephrol Hypertens; 2018 Nov; 27(6):420-425. PubMed ID: 30020140
[TBL] [Abstract][Full Text] [Related]
2. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.
Coleman CI; Peacock WF; Antz M
Heart Lung Circ; 2018 Mar; 27(3):390-393. PubMed ID: 28528780
[TBL] [Abstract][Full Text] [Related]
4. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
5. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
G Ital Nefrol; 2017 Apr; 34(2):58-73. PubMed ID: 28682563
[TBL] [Abstract][Full Text] [Related]
6. Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.
Heine GH; Brandenburg V; Schirmer SH
Dtsch Arztebl Int; 2018 Apr; 115(17):287-294. PubMed ID: 29789105
[TBL] [Abstract][Full Text] [Related]
7. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.
Trevisan M; Hjemdahl P; Clase CM; de Jong Y; Evans M; Bellocco R; Fu EL; Carrero JJ
Am J Kidney Dis; 2023 Mar; 81(3):307-317.e1. PubMed ID: 36208798
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.
Kooiman J; van Rein N; Spaans B; van Beers KA; Bank JR; van de Peppel WR; del Sol AI; Cannegieter SC; Rabelink TJ; Lip GY; Klok FA; Huisman MV
PLoS One; 2014; 9(5):e94420. PubMed ID: 24817475
[TBL] [Abstract][Full Text] [Related]
9. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
10. Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study.
Himmler S; Müller M; Ostwald D; Seddik A; Basic E; Hradetzky E
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):223-230. PubMed ID: 30295561
[TBL] [Abstract][Full Text] [Related]
11. Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey.
Potpara TS; Lenarczyk R; Larsen TB; Deharo JC; Chen J; Dagres N;
Europace; 2015 Dec; 17(12):1862-7. PubMed ID: 26733617
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
13. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
Van Der Meersch H; De Bacquer D; De Vriese AS
Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
[TBL] [Abstract][Full Text] [Related]
14. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Bansal VK; Herzog CA; Sarnak MJ; Choi MJ; Mehta R; Jaar BG; Rocco MV; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):859-868. PubMed ID: 28941763
[TBL] [Abstract][Full Text] [Related]
15. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
[TBL] [Abstract][Full Text] [Related]
16. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
Martinez C; Katholing A; Wallenhorst C; Freedman SB
Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
[TBL] [Abstract][Full Text] [Related]
17. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
[TBL] [Abstract][Full Text] [Related]
18. Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis.
Su X; Yan B; Wang L; Lv J; Cheng H; Chen Y
Am J Kidney Dis; 2021 Nov; 78(5):678-689.e1. PubMed ID: 33872690
[TBL] [Abstract][Full Text] [Related]
19. Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Potpara TS; Jokic V; Dagres N; Larsen TB; Lane DA; Hindricks G; Lip GY
Curr Med Chem; 2016; 23(19):2055-69. PubMed ID: 26861000
[TBL] [Abstract][Full Text] [Related]
20. [Anticoagulation and anti platelet therapy in patients with chronic kidney disease].
Schirmer SH; Brandenburg V; Antlanger M
Dtsch Med Wochenschr; 2019 Oct; 144(20):1423-1427. PubMed ID: 31594017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
